Pirkalkhoran Sama, Grabowska Wiktoria Roksana, Kashkoli Hamid Heidari, Mirhassani Reihaneh, Guiliano David, Dolphin Colin, Khalili Hanieh
School of Biomedical Science, University of West London, London W5 5RF, UK.
Nivad Pharmed Salamat Company Research Center, Tehran 1455714138, Iran.
Bioengineering (Basel). 2023 Jan 17;10(2):122. doi: 10.3390/bioengineering10020122.
Antibody fragments are used in the clinic as important therapeutic proteins for treatment of indications where better tissue penetration and less immunogenic molecules are needed. Several expression platforms have been employed for the production of these recombinant proteins, from which and CHO cell-based systems have emerged as the most promising hosts for higher expression. Because antibody fragments such as Fabs and scFvs are smaller than traditional antibody structures and do not require specific patterns of glycosylation decoration for therapeutic efficacy, it is possible to express them in systems with reduced post-translational modification capacity and high expression yield, for example, in plant and insect cell-based systems. In this review, we describe different bioengineering technologies along with their opportunities and difficulties to manufacture antibody fragments with consideration of stability, efficacy and safety for humans. There is still potential for a new production technology with a view of being simple, fast and cost-effective while maintaining the stability and efficacy of biotherapeutic fragments.
抗体片段在临床上用作重要的治疗性蛋白质，用于治疗需要更好的组织穿透性和免疫原性较低分子的适应症。已经采用了几种表达平台来生产这些重组蛋白，其中基于大肠杆菌和CHO细胞的系统已成为最有希望实现高表达的宿主。由于诸如Fab和scFv之类的抗体片段比传统抗体结构小，并且治疗效果不需要特定的糖基化修饰模式，因此有可能在翻译后修饰能力降低且表达产量高的系统中表达它们，例如在基于植物和昆虫细胞的系统中。在这篇综述中，我们描述了不同的生物工程技术以及它们在制造抗体片段时所面临的机遇和困难，同时考虑到对人类的稳定性、疗效和安全性。从简单、快速且具有成本效益的角度来看，同时保持生物治疗片段的稳定性和疗效，新型生产技术仍具有潜力。
